BioMarin Pharmaceutical (BMRN) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed BioMarin Pharmaceutical (BMRN) over the past year, gaining 285.3% versus a gain of 10.5%. Over five years, BMRN leads with a -31.0% price change compared with -42.0% for SYRE. BioMarin Pharmaceutical is the larger company by market cap ($11.70 billion vs $8.88 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRN | SYRE |
|---|---|---|
| Share price | $60.41 | $93.47 |
| Market cap | $11.70B | $8.88B |
| 1-day change | -1.64% | -4.26% |
| YTD return | +1.65% | +185.32% |
| 1-year return | +10.46% | +285.28% |
| 5-year return | -31.02% | -42.03% |
| Forward P/E | 9.60 | — |
| EPS (TTM) | $-0.10 | $-2.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.22B | $0 |
| Revenue growth (YoY) | +12.87% | — |
| Net income (latest FY) | $348.90M | $-155.20M |
| Gross margin | 77.73% | — |
| Operating margin | 12.71% | — |
| Net margin | 10.83% | — |
| 52-week high | $70.98 | $110.64 |
| 52-week low | $49.26 | $24.58 |
| Distance from 52-week high | -14.89% | -15.52% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +49.48% | +32.52% |
| Average volume | 2.35M | 1.26M |
| Shares outstanding | 193.69M | 94.97M |
| Employees | 3,221 | 130 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed BMRN by 274.8 percentage points over the past year.
About BioMarin Pharmaceutical
BMRN stock →BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
BMRN vs SYRE FAQ
Which is bigger, BioMarin Pharmaceutical or Spyre Therapeutics?
BioMarin Pharmaceutical (BMRN) is larger, with a market capitalization of $11.70B compared with $8.88B for Spyre Therapeutics (SYRE).
Which stock has performed better over the past year, BMRN or SYRE?
SYRE returned +285.28% over the past 12 months, compared with +10.46% for BMRN (price return, excluding dividends). Past performance does not predict future results.
Are BioMarin Pharmaceutical and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.